Table 1.

Baseline demographics

		Median (IQR)/n(%)
Age (years)		66(61–71)
Initial PSA (ng/mL)		8.2(5.3–15.5)
Pathologic T stage	2	741(46.3)
	3	825(51.6)
	4	33(2.1)
Lymph node metastasis	(−)	1555(97.2)
	(+)	45(2.8)
Pathologic Gleason score	≤6	434(27.1)
	7	780(48.8)
	≥8	386(24.1)
LVI	(−)	1482(92.6)
	(+)	118(7.4)
Margin status	(−)	840(52.5)
	(+)	760(47.5)
BCR	No	934(58.4)
	Yes	666(41.6)
Distant metastasis	Present	1505(94.1)
	Absent	95(5.9)
Cancer-specific mortality	Survived	1552(97.0)
	Expired	48(3.0)
Follow-up duration (months)		33.1(18.4–53.8)

LVI lymphovascular invasion; PSA prostate-specific antigen; NHT neoadjuvant hormone therapy; BCR biochemical recurrence